Intensive Care Outcome Prediction Using Admission Carbohydrate-deficient Transferrin

NCT07632716 | Not Yet Recruiting

• 1 other identifier: 1302/2026
• Study Type: observational
• Target: 800
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this observational study is to learn whether hazardous alcohol consumption, measured objectively by carbohydrate-deficient transferrin (CDT) levels at intensive care unit (ICU) admission, is associated with worse outcomes in critically ill patients. The main question it aims to answer is: Do elevated CDT levels at ICU admission predict increased short-term mortality and adverse clinical outcomes in adult non-traumatic ICU patients? Participants admitted to the intensive care unit via the emergency department will have CDT levels measured as part of the study. Researchers will then collect and analyze clinical data, including mortality, duration of mechanical ventilation, delirium, ICU length of stay, renal replacement therapy, and ICU readmission rates, during hospitalization and follow-up.

Conditions

Intensive Care (ICU); Critical Illness; Alcohol Misuse

Keywords

Alcohol-Related Disorders; Critical Illness; Intensive Care Units

Outcome Measures

Primary Outcomes (1)

• The primary outcome of the study is 30-day all-cause mortality in ICU patients.

  30-day all-cause mortality is defined as death from any cause occurring within 30 days after ICU admission. Mortality status will be assessed using patient medical records and, if unavailable, through the Austrian "Zentrales Personenstandsregister" (Central Civil Status Register), which documents registered deaths. Outcomes will be compared between patients with elevated and non-elevated carbohydrate-deficient transferrin (CDT) levels measured at ICU admission.

  From ICU admission to 30 days after ICU admission

Secondary Outcomes (7)

• In-hospital mortality

  From hospital admission to hospital discharge evaluated 6 Months after study inclusion

• ICU length of stay

  From ICU admission to ICU discharge evaluated 6 Months after study inclusion

• Duration of mechanical ventilation

  From initiation of mechanical ventilation to successful discontinuation during ICU stay evaluated 6 Months after study inclusion

• Illness severity score

  Evaluated from the documentation 6 Months after study inclusion

• Illness severity score

  Evaluated from the documentation 6 Months after study inclusion

Interventions

Carbohydrate-Deficient Transferrin (CDT) Measurement DIAGNOSTIC_TEST

Carbohydrate-deficient transferrin (CDT) measurement is performed at ICU admission as an objective biomarker of sustained hazardous alcohol consumption during the previous 1-3 weeks. CDT values are obtained from routinely collected blood samples in adult non-traumatic ICU patients admitted via the emergency department. The study is purely observational and does not involve administration of a therapeutic intervention or changes to standard clinical care. CDT levels are analyzed in relation to outcomes including 30-day mortality, ICU length of stay, mechanical ventilation, delirium, renal replacement therapy, and ICU readmission.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Study participants will be selected from adult patients admitted to the Department of Emergency Medicine who are subsequently transferred to an in-house intensive care unit (ICU). The study population consists of critically ill non-traumatic ICU patients receiving routine emergency and intensive care treatment.

You may qualify if:

• all patients ≥ 18 admitted to the Department of Emergency Medicine and subsequently transferred to an in-house intensive care unit (ICU)

You may not qualify if:

• Patients transferred to other hospital departments prior to completion of intensive care
• Patients admitted directly to the ICU without passing the ED
• Patients admitted to intermediate care units
• Patients with pre-existing or newly diagnosed hepatic cirrhosis
• Patients with known or obvious pregnancy will be excluded.
• Patients with no vascular access

Sponsors & Collaborators

• Medical University of Vienna: lead

MeSH Terms

Conditions

Critical Illness; Alcohol-Related Disorders

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Central Study Contacts

Juergen Grafeneder, MD, PhD MSc

CONTACT

‭+43 1 4040019640‬; juergen.grafeneder@meduniwien.ac.at

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: May 27, 2026
• First Posted: June 8, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): June 1, 2028
• Study Completion (Estimated): July 1, 2028
• Last Updated: June 8, 2026

Record last verified: 2026-06